These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24548858)

  • 41. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
    Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
    Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.
    Kriegl L; Jung A; Horst D; Rizzani A; Jackstadt R; Hermeking H; Gallmeier E; Gerbes AL; Kirchner T; Göke B; De Toni EN
    PLoS One; 2012; 7(12):e51654. PubMed ID: 23284732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
    Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
    Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
    Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
    Hutchins G; Southward K; Handley K; Magill L; Beaumont C; Stahlschmidt J; Richman S; Chambers P; Seymour M; Kerr D; Gray R; Quirke P
    J Clin Oncol; 2011 Apr; 29(10):1261-70. PubMed ID: 21383284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
    J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.
    Donehower LA; Creighton CJ; Schultz N; Shinbrot E; Chang K; Gunaratne PH; Muzny D; Sander C; Hamilton SR; Gibbs RA; Wheeler D
    J Pathol; 2013 Jan; 229(1):99-110. PubMed ID: 22899370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
    Nodin B; Zendehrokh N; Sundström M; Jirström K
    Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J; Sun ZW; Li YY; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
    JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
    Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
    J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
    Souglakos J; Philips J; Wang R; Marwah S; Silver M; Tzardi M; Silver J; Ogino S; Hooshmand S; Kwak E; Freed E; Meyerhardt JA; Saridaki Z; Georgoulias V; Finkelstein D; Fuchs CS; Kulke MH; Shivdasani RA
    Br J Cancer; 2009 Aug; 101(3):465-72. PubMed ID: 19603024
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.
    Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K
    Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.